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Abstract: 
Objectives: To evaluate the performance of five CVD risk scores developed in diabetes 
populations and compare their performance to QRISK2. 
Research Design and Methods: A cohort of people diagnosed with type 2 diabetes between 
2004 and 2013 was identified from the Scottish national diabetes register. CVD events were 
identified using linked hospital and death records. Five-year risk of CVD was estimated using 
each of QRISK2, ADVANCE, Cardiovascular Healthy Study (CHS), New Zealand Diabetes 
Cohort Study (DCS), Fremantle, and the Swedish National Diabetes Register (NDR) risk 
scores. Discrimination and calibration was assessed using Harrell’s C-statistic and calibration 
plots, respectively.  
Results: The external validation cohort consisted of 181,399 people with type 2 diabetes and 
no history of CVD. There were 14,081 incident CVD events within five years follow-up. The 
five-year observed risk of CVD was 9·7% (95% CI: 9·6, 9·9). C-statistics varied between 
0·66 and 0·67 for all risk scores. QRISK2 overestimated risk, classifying 87% to be at high 
risk for developing CVD within five years; ADVANCE underestimated risk and the Swedish 
NDR risk score calibrated well to observed risk.  
Conclusions: None of the risk scores performed well among people with newly diagnosed 
type 2 diabetes and QRISK2 had the worst performance. Using these risk scores to predict 
five-year CVD risk in this population may not be appropriate.  
  
  
Introduction:  
Despite improvements through earlier diagnoses and improved treatments,{ ADDIN 
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(CVD) mortality and morbidity risk among people with type 2 diabetes remains markedly 
higher than in people without diabetes{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. The 
  
effect size depends on the sub-type of CVD as well as age, sex, diabetes duration, ethnicity 
and socio-economic status.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}  
Accurate CVD risk estimation in people with type 2 diabetes without established 
CVD can identify patients at high risk of developing CVD and can thus be used to guide 
appropriate treatment, for example with statins, illustrate to patients the likely effects of 
lifestyle choices and identify eligible participants for clinical trials. The United Kingdom 
(UK) clinical guideline network, the National Institute of Health and Clinical Excellence 
(NICE) recently updated its guidelines to advocate using the QRISK2 score,{ ADDIN 
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num></record></Cite></EndNote>} to ascertain CVD risk in people with type 2 diabetes. 
Despite this recommendation, risk scores developed in the general population may 
underestimate CVD risk in individuals with diabetes{ ADDIN EN.CITE 
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QRISK2 has not been independently, externally validated in people with type 2 diabetes.  
Several CVD risk scores have also been developed specifically for use among people 
with type 2 diabetes.{ ADDIN EN.CITE 
<EndNote><Cite><Author>Chamnan</Author><Year>2009</Year><RecNum>10</RecNu
m><DisplayText><style face="superscript">[8]</style></DisplayText><record><rec-
number>10</rec-number><foreign-keys><key app="EN" db-
id="fwesxfrtxvr0anezpwd5vvv02st9prex2za9" 
timestamp="1425570468">10</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Chamnan, 
P.</author><author>Simmons, R. K.</author><author>Sharp, S. 
J.</author><author>Griffin, S. J.</author><author>Wareham, N. 
J.</author></authors></contributors><titles><title>Cardiovascular risk assessment scores for 
people with diabetes: a systematic review</title><secondary-title>Diabetologia</secondary-
  
title><alt-title>Diabetologia</alt-title></titles><periodical><full-title>Diabetologia</full-
title><abbr-1>Diabetologia</abbr-1></periodical><alt-periodical><full-
title>Diabetologia</full-title><abbr-1>Diabetologia</abbr-1></alt-periodical><pages>2001-
2014</pages><volume>52</volume><number>10</number><keywords><keyword>Cardio
vascular 
disease</keyword><keyword>Diabetes</keyword><keyword>Prediction</keyword><keyw
ord>Risk score</keyword><keyword>Systematic 
review</keyword></keywords><dates><year>2009</year><pub-
dates><date>2009/10/01</date></pub-dates></dates><publisher>Springer-
Verlag</publisher><isbn>0012-186X</isbn><urls><related-
urls><url>http://dx.doi.org/10.1007/s00125-009-1454-0</url></related-
urls></urls><electronic-resource-num>10.1007/s00125-009-1454-0</electronic-resource-
num><language>English</language></record></Cite></EndNote>} While most of the 
earliest diabetes-specific CVD risk scores, such as the United Kingdom Prospective Diabetes 
Study (UKPDS) risk engine have been extensively externally validated, many of the 
contemporary risk scores have not.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} Though 
one recent study did externally validate several contemporary risk scores,{ ADDIN EN.CITE 
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limited by small sample sizes of the external validation cohorts resulting in imprecise 
estimates of calibration and discrimination.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} 
In addition, few external validation studies have been conducted on statin-naïve participants.  
Scotland maintains a national register of all patients with a diagnosis of type 2 
diabetes, and this register can be linked to population-based hospitalisation and mortality 
records. Consequently, this data source offers an opportunity to explore the performance of 
existing risk scores in a contemporary population of people with type 2 diabetes. 
We evaluated the predictive performance of five diabetes-specific CVD risk scores in 
an external validation cohort of people with type 2 diabetes in Scotland and compared their 
performance to QRISK2.  
  
Research Design & Methods:  
Study design and participants:  
Data for these analyses were obtained from the population-wide Scottish Care Information-
Diabetes (SCI-Diabetes) database. This dynamic clinical register was established in 2000 and 
is populated by patient data from primary care and hospital diabetes clinics. Outcome data 
were obtained from linkage to the Scottish Morbidity records (SMR01), a national hospital 
admission dataset, and death registrations. Approval for generation and analysis of the linked 
dataset was obtained from the Caldicott guardians of all Health Boards in Scotland, the 
Privacy Advisory Committee of the Information Services Division of NHS National Services 
Scotland (ISD) and the multi-centre research ethics committee. 
The external validation cohort consisted of people diagnosed with type 2 diabetes 
between 1st January 2004 and 1st June 2016 in Scotland. This time-frame was chosen since 
SCI-Diabetes achieved over 99% completeness of primary and secondary care clinics from 
2004 onwards. The cohort was restricted to people who had no previous history of CVD (as 
defined below) and who were aged between 30 and 89 years at date of diagnosis of diabetes 
due to small numbers of people in other age groups. We excluded people with a history of 
CVD at diagnosis of diabetes from our cohort because of all except one of the risk scores we 
wished to validate were designed to estimate risk of incident CVD. We included individuals 
who were prescribed statins prior to and following type 2 diabetes diagnosis in the main 
analyses but conducted sensitivity analyses in sub-populations restricted to i) people who had 
not been prescribed statins prior to type 2 diabetes diagnosis ii) people who had not been 
prescribed statins prior to type 2 diabetes diagnosis or during follow-up. 
Members of the cohort were followed up from baseline, defined as date of diabetes 
diagnosis, until date of death, date of first CVD event or study end-date (1st June 2016), 
whichever came first.  
  
Outcome: 
CVD was defined as any hospital admission or death from myocardial infarction, stroke, 
unstable angina, transient ischaemic attack, peripheral vascular disease and coronary, carotid, 
or major amputation procedures between baseline and 1st June 2016. International 
Classification of Disease, version 10, codes were used to identify CVD: I20-25, I46, I60-69, 
G45, I73·9, I74·3, I74·5, E11·5, E14·5. { HYPERLINK 
"https://en.wikipedia.org/wiki/Office_of_Population_Censuses_and_Surveys" \o "Office of 
Population Censuses and Surveys" } Classification of Interventions and Procedures version 4 
(OPCS-4) codes were used for coronary, carotid and major (non-traumatic) amputation 
procedures: K40-K46, K48, K49, K50, K75, L29-L31, L33-35 and X09·3-X09·5, 
respectively.  
Selected risk scores: 
QRISK2 was developed using data from the QRESEARCH database, is based upon a Cox 
proportional hazard model and predicts 10-year risk of CVD.{ ADDIN EN.CITE 
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ADDIN EN.CITE { ADDIN EN.CITE.DATA }} were chosen as these were developed to 
predict CVD while the remaining risk scores predict only coronary heart disease or stroke. 
Since the publication of the systematic review, an additional risk score, the Atherosclerosis 
Risk in Communities (ARIC) risk score for CVD has been developed.{ ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }} However, this risk score includes several predictors (alcohol 
consumption, physical activity) which are not available in SCI-Diabetes and linked data 
sources and so was not considered in this validation exercise.  
The characteristics of QRISK2 and the five diabetes-specific risk scores are presented in 
Table 1. All five diabetes-specific risk scores were derived from Cox proportional hazards 
models; three predict five-year risk, while CHS predicts 10-year risk and ADVANCE 
predicts four-year risk. The five-year baseline hazard for QRISK2 has been published while 
the five-year baseline hazards were obtained from the study investigators for CHS and were 
estimated by extrapolation for ADVANCE.  
Predictors used in risk models:  
Taken together, the selected CVD risk prediction models contain the following predictors: 
age, sex, diabetes status (type 1/type 2/no diabetes), diabetes duration, ethnicity, Townsend 
deprivation score, systolic blood pressure, pulse pressure, smoking status, body mass index, 
total:HDL-cholesterol ratio, HDL-cholesterol, non-HDL cholesterol, glycated haemoglobin, 
glucose-lowering medications, micro/macro albuminuria, albumin-creatinine ratio, creatinine, 
family history of CVD, anti-hypertensive medications, lipid-lowering medications, 
retinopathy, chronic kidney disease, rheumatoid arthritis and atrial fibrillation.  
  
Definitions of predictors in external validation cohort 
Baseline predictor values were defined as measurements recorded closest to baseline, no 
more than 24 months prior to or 12 months after date of diagnosis of diabetes. Any predictor 
without a measurement within this timeframe was declared missing. Prescriptions of anti-
hypertensive and lipid-lowering medications occurring within the three months preceding 
baseline date were defined using British National Formulary (BNF) codes 2·5 and 2·12, 
respectively. Chronic kidney disease was defined as a recording of estimated glomerular 
filtration rate of <60ml/min/1·73m2 and/or a hospital admission for chronic kidney disease 
(ICD-10 codes: N18, I12-13, ICD-9 codes: 585).  
Some predictors were not available, or had different definitions compared to the five scores 
within SCI-Diabetes and linked datasets and, therefore, some proxy predictors were used. 
Presence of rheumatoid arthritis was defined as patients with any prescription for disease 
modifying anti-rheumatic drugs, defined with a BNF code of 10·1·3 prior to baseline. Atrial 
fibrillation was defined as a hospital admission record, including diagnosis codes for atrial 
fibrillation (ICD10: I48, ICD9: 427·3) or a warfarin prescription in the absence of a hospital 
record of prior deep vein thrombosis or pulmonary embolism.{ ADDIN EN.CITE 
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1). Family history was estimated as the conditional probability of having a family history of 
CVD based on age and deprivation status (SIMD) using data from the 2014 Scottish Health 
  
Survey (see Supplementary table 2).{ ADDIN EN.CITE 
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We conducted sensitivity analyses whereby all proxy categorical predictors (atrial fibrillation, 
rheumatoid arthritis, family history of CVD) were set to null and where the Townsend score 
was set to the mean. Further sensitivity analyses were conducted to include prevalent diabetes 
whereby baseline was defined as the latest of 01-01-2010, date of diabetes diagnosis or date 
of 30th birthday. Lastly, we examined whether the predictive performance of the selected risk 
scores changed over time (based on diagnosis diabetes before or during/after 2011). 
Statistical analyses:  
Missing predictor data were imputed using multiple imputation assuming data were missing 
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and the outcome (follow-up time and CVD event) and was used to generate 20 imputed 
datasets. Estimates were pooled using Marshall’s adaption of Rubin’s rules.{ ADDIN 
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also conducted as additional sensitivity analyses.  
Observed five-year risk of CVD was estimated using the Kaplan-Meier estimator. Five-year 
risk of CVD was estimated at time of type 2 diabetes diagnosis using the five selected CVD 
risk scores and QRISK2. The predictive performance of the selected risk scores was assessed 
by examining measures of calibration and discrimination. Calibration describes how closely 
the predicted five-year risk and the observed five-year risk agree and was assessed by plotting 
smoothed observed incidence by predicted incidence using Kaplan-Meier estimates.{ ADDIN 
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Calibration-in-the-large statistics and calibration slopes for which values of 0 and 1, 
respectively, indicate good calibration were also calculated. Calibration-in-the-large statistics 
  
compare the mean predicted risk and mean observed risks. Calibration statistics were also 
calculated for the recalibrated risk scores following adjustment of the baseline hazard to that 
of the external validation cohort.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} 
Discrimination describes the model’s ability to differentiate between patients who developed 
CVD to those that did not and was assessed here by calculating Harrell’s C-statistic. This 
statistic describes the probability that, for any pair of individuals among whom one developed 
CVD and the other did not develop CVD, the predicted risk of the outcome is higher for the 
individual who did subsequently develop the disease.{ ADDIN EN.CITE 
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A C-statistic of 1 denotes perfect discrimination and a value of 0.5 denotes a prediction 
model that performs no better than a flip of a coin.  
We calculated the number of people classified as high risk, based on the cut-off point in 
national clinical guidelines (≥10% estimated risk in QRISK2) or low risk (<10% estimated 
risk in QRISK2).{ ADDIN EN.CITE <EndNote><Cite><Author>National Institute for 
Health and Care 
Excellence</Author><Year>2014</Year><RecNum>565</RecNum><DisplayText><style 
face="superscript">[6]</style></DisplayText><record><rec-number>565</rec-
number><foreign-keys><key app="EN" db-
id="awe0xfst009dpuew5s0xdvwk2f2dvw20900s" 
timestamp="1517283005">565</key></foreign-keys><ref-type name="Report">27</ref-
type><contributors><authors><author>National Institute for Health and Care 
Excellence,</author></authors></contributors><titles><title>Cardiovascular disease: risk 
assessment and reduction, including lipid 
modification</title></titles><dates><year>2014</year><pub-dates><date>July 
2014</date></pub-dates></dates><urls></urls></record></Cite></EndNote>} 
All statistical analyses were carried out in R version 3·2·2 (2015-08-14).  Calibration plots 
were generated using the rms package in R.{ ADDIN EN.CITE 
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Results 
There were 218,607 individuals diagnosed with type 2 diabetes in Scotland between January 
2004 and June 2016 (Table 2). Of these, 37,208 had a previous history of cardiovascular 
disease and were excluded from the analyses, leaving 181,399 individuals to form the 
external validation cohort. Of the 26 predictors included in the risk models, 11 had missing 
values and the average missingness was 18%. There were a total of 118,098 individuals with 
incomplete predictor data, including 33,210 individuals with a single incomplete predictor 
and a further 42,834 individuals with two incomplete variables only (Supplementary Table 
3). 
Overall, there were 14,081 incident CVD events during 673,740 person-years of follow-up 
and the five-year observed Kaplan-Meier risk of CVD was 9·7% (95% CI: 9·6, 9·9). The 
median follow-up time was 5 years and there were 91,549 individuals who were followed-up 
for at least five years. There were 10,023 non-CVD deaths during follow-up.  
Within the external validation cohort, 36,471 individuals had been prescribed statins prior to 
date of diabetes diagnosis. During follow-up, 71,585 individuals were prescribed statins and 
the median time until statin initiation was 141 days. 
Calibration & Discrimination 
  
Measures of calibration and discrimination are presented in Table 3 and calibration plots are 
presented in Figure 1. Briefly, the agreement between observed and predicted risks 
(calibration-in the-large) was better using the Swedish NDR, CHS and NZ DCS risk scores 
than for the QRISK2 and ADVANCE risk scores. Overall, QRISK2 overestimated risk while 
ADVANCE underestimated risk across all risk groups. C-statistics for each of the models 
ranged between 0.663 (0.658, 0.668) and 0.674 (0.669, 0.679) for the whole population. 
These values decreased following stratification by age, particularly in older age groups. 
Supplementary Figure 1 presents the distribution of predicted risks for each risk score. 
After recalibration of the risk scores, calibration improved slightly for the ADVANCE risk 
score (Supplementary Figure 2). The agreement between observed and predicted risks 
estimated by QRISK2 deteriorated further. The median predicted risk estimated by the 
recalibrated QRISK2, ADVANCE, CHS, Fremantle Diabetes Study, NZ DCS and the 
Swedish NDR risk scores were 94·7%, 2·5%, 4·7%, 4·1%, 6·5% and 6·4%. 
Risk Classification 
With a 10% threshold for high risk of developing CVD, QRISK2 classified 86·8% of the 
cohort as high risk, capturing 13,633 (96·8%) of the subsequent CVD events. In comparison, 
3·2%, 58·8%, 25·8%, 82·6% and 37·3% of the cohort were classified as high risk, capturing 
8·4%, 80·8%, 59·2%, 94·7% and 46% of the CVD events using the ADVANCE, CHS, 
Fremantle, NZ DCS and Swedish NDR risk scores, respectively (Supplementary Table 4)  
Sensitivity Analyses 
  
Among the subset of individuals who were not prescribed statins prior to diabetes diagnosis 
(n=144,928), there were 9,572 events during 533,006 person-years of follow-up. Measures of 
calibration and discrimination for this subset yielded similar results to the main analyses 
(Supplementary Figure 3 and Supplementary Table 5). These findings were also replicated in 
the subset of individuals who were not prescribed statins prior to diabetes diagnosis or during 
follow-up (Supplementary Figure 4, Supplementary Table 5), when proxy variables were 
replaced with null or mean values (Supplementary Figure 5, Supplementary Table 5), when 
people with prevalent diabetes were included in the cohort (Supplementary Figure 6, 
Supplementary Table 6) and when complete case analyses were used omitting missing data 
(Supplementary Figure 7, Supplementary Table 5). The predictive performance of each of the 
risk scores varied only slightly depending on year of diabetes diagnosis (<2011 vs. ≥2011) 
(Supplementary Table 5).   
Conclusions:  
Using a population-wide diabetes dataset, we have conducted the largest external validation 
of several contemporary CVD risk scores among people with type 2 diabetes to date and 
conducted the first external evaluation of QRISK2, the recommended CVD risk score for 
people with type 2 diabetes in England and Wales.  
The ability of the assessed risk scores to discriminate between people who did and did not 
develop incident CVD as assessed by Harrell’s C-statistics was similar with all C-statistics 
for all risk scores below 0·68. The median predicted risk using QRISK2 was 23·5% 
compared to an observed risk of 9·3% and QRISK2 classified over 86% of people with type 2 
diabetes as high risk. Compared to QRISK2, the agreement between predicted and observed 
risks using the risk scores developed in diabetes populations were generally better. For 
example, the median predicted risk using the CHS and Swedish NDR risk scores was 11·7% 
and 8·3%, respectively. The ADVANCE risk score exhibited the poorest calibration and 
  
severely underestimated risk of CVD in people with type 2 diabetes in Scotland. 
Recalibration by adjustment of the baseline hazard worsened the performance of QRISK2. 
More advanced recalibration approaches, such as the adjustment of predictor regression 
coefficients, are required to ensure better agreement between QRISK2 predicted and 
observed risks in people with type 2 diabetes in Scotland.{ ADDIN EN.CITE 
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Findings from other studies: 
Although UK national clinical guidelines recommend the use of QRISK2 to estimate CVD 
risk in people with type 2 diabetes, the performance of QRISK2 in estimating CVD risk in 
external populations has not previously been assessed. However, an evaluation of the 
performance of QRISK2 in people with type 2 diabetes has been made using a subset of 
people with type 2 diabetes in the QRESEARCH database and is described in an online 
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the discriminative ability of QRISK2 were better in this evaluation than in our validation (C-
statistics: 0·703 [0·691, 0·715] in women and 0·696 [0·685, 0·706] in men) while the 
agreement between predicted and observed risks was good.  
Most previous studies have reported that CVD risk scores developed in general populations 
underestimate risk in people with type 2 diabetes,{ ADDIN EN.CITE 
<EndNote><Cite><Author>Chamnan</Author><Year>2009</Year><RecNum>10</RecNu
m><DisplayText><style face="superscript">[8]</style></DisplayText><record><rec-
number>10</rec-number><foreign-keys><key app="EN" db-
id="fwesxfrtxvr0anezpwd5vvv02st9prex2za9" 
timestamp="1425570468">10</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Chamnan, 
P.</author><author>Simmons, R. K.</author><author>Sharp, S. 
J.</author><author>Griffin, S. J.</author><author>Wareham, N. 
J.</author></authors></contributors><titles><title>Cardiovascular risk assessment scores for 
people with diabetes: a systematic review</title><secondary-title>Diabetologia</secondary-
  
title><alt-title>Diabetologia</alt-title></titles><periodical><full-title>Diabetologia</full-
title><abbr-1>Diabetologia</abbr-1></periodical><alt-periodical><full-
title>Diabetologia</full-title><abbr-1>Diabetologia</abbr-1></alt-periodical><pages>2001-
2014</pages><volume>52</volume><number>10</number><keywords><keyword>Cardio
vascular 
disease</keyword><keyword>Diabetes</keyword><keyword>Prediction</keyword><keyw
ord>Risk score</keyword><keyword>Systematic 
review</keyword></keywords><dates><year>2009</year><pub-
dates><date>2009/10/01</date></pub-dates></dates><publisher>Springer-
Verlag</publisher><isbn>0012-186X</isbn><urls><related-
urls><url>http://dx.doi.org/10.1007/s00125-009-1454-0</url></related-
urls></urls><electronic-resource-num>10.1007/s00125-009-1454-0</electronic-resource-
num><language>English</language></record></Cite></EndNote>} so we were surprised to 
find that QRISK2 overestimated risk in our external validation cohort. However, this 
difference may be partly explained by the inclusion of prevalent type 2 diabetes patients in 
the QRISK2 derivation cohort, as shown by sensitivity analyses in which people with 
prevalent type 2 diabetes were included in the external validation cohort (Supplementary 
Figure 6). Including diabetes in the risk score as a categorical variable and in an interaction 
with age as in this risk score and others is unlikely to sufficiently capture the complex 
relationship between diabetes and CVD, particularly the effect of diabetes duration on CVD 
risk. Our finding that QRISK2 was unable to accurately discriminate between people who did 
and did not develop CVD is less surprising given the relative homogeneity of the external 
validation cohort compared to the derivation cohort.  
Previous validation studies of contemporary diabetes-specific risk scores are limited. One 
recent external validation study assessed the performance of the five diabetes-specific risk 
  
scores in three separate cohorts; the European Prospective Investigation into Cancer and 
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num></record></Cite></EndNote>} Expected to observed ratios varied between 1·06 (0·81, 
1·40) and 1·46 (1·04, 2·05). The risk scores exhibited poor discriminative ability in the three 
external validation cohorts with C-statistics ranging from 0·54 (0·46, 0·63) for the CHS risk 
score in EPIC-NL to 0·69 (0·59, 0·79) for the Fremantle risk score in SMART. Within each 
  
external validation cohort, the discriminative ability was similar for each risk score, a finding 
replicated in the present study and a possible reflection of the limitations of Harrell’s C-
statistic in the presence of extensive censoring.{ ADDIN EN.CITE 
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Unfortunately, the wide confidence intervals owing to the small numbers of events in each 
external validation cohort (52 events in EPIC-NL, 73 in EPIC-Potsdam and 58 in SMART) 
made interpretation of the performance of these models difficult and prevented the authors 
identifying the strongest performing risk score. The ADVANCE risk score was externally 
  
validated in 1,836 patients enrolled in the DIABHYCAR clinical trial and exhibited similar 
discrimination (C-statistic: 0·69 [0·65, 0·72]) as reported here, but it underestimated risk in 
the DIABHYCAR population.{ ADDIN EN.CITE 
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Beyond differences in the performance of different health systems, there are likely to be a 
number of explanations for the overall poor performance of the assessed risk scores.{ ADDIN 
EN.CITE 
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urls></urls><electronic-resource-num>10.1136/bmj.i3140</electronic-resource-
num></record></Cite></EndNote>} One major potential explanation is differences in the 
distribution of outcomes and predictors (i.e. the case mix) in the external validation cohort 
compared to the derivation cohorts. Different age distributions are likely to be the most 
important difference between development and this external validation cohort, as indicated by 
the age-stratified measures of discrimination and calibration in Table 3. A further factor 
which may have contributed to poor performance in this cohort are different eligibility 
  
criteria. For example, ADVANCE was a trial with strict inclusion criteria that made for a 
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num></record></Cite></EndNote>} Definitions of CVD also varied between derivation and 
validation cohorts. While QRISK2 identifies angina through general practice records, the 
present study only includes hospital admissions for angina and therefore angina incidence 
will be underestimated. Other factors which may have contributed to the poor performance of 
these risk scores was the use of proxies, different time frames of the outcome (10-year 
development vs. 5-year validation) and potentially differences in patterns of glucose-lowering 
therapies that may have different effects on CVD risks.   
  
Strengths/Weaknesses: 
This study had a number of strengths. By utilising population-based registers we were able to 
assemble the largest external validation cohort of people with type 2 diabetes to assess and 
directly compare the performance of several CVD risk scores to date. The large cohort also 
enabled the assessment of each model’s performance in subsets of people based upon statin 
exposure. The population-based nature of these data also ensured low risk of selection biases 
influencing our findings and enabled us to present results which are applicable to the entire 
population of Scotland.  
A number of weaknesses of the study should be acknowledged. Firstly, the use of proxy 
measures for some of the predictor variables may have contributed to the poor performance 
of the models for which these were required. However, by conducting sensitivity analyses to 
explore the likely effect of using these proxy measures, we have shown that this limitation is 
unlikely to have had a large effect on the overall findings of our study. A related limitation 
was the presence of missing data among the predictors. To handle this problem we chose to 
multiply impute missing values, a missing data approach which reduces the shortcomings of 
complete case analysis.{ ADDIN EN.CITE 
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ated-urls></urls><electronic-resource-num>10.1080/01621459.1996.10476908</electronic-
resource-num><access-date>2015/03/26</access-date></record></Cite></EndNote>} 
Concerns surrounding the accuracy of the recording of CVD events may be a further 
limitation of this work. Nonetheless, findings from the West of Scotland Coronary 
Prevention Study (WOSCOPS) indicated that linkage to hospital admissions registers for 
acquiring CVD events may be as effective as direct patient contact.{ ADDIN EN.CITE 
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7</electronic-resource-num></record></Cite></EndNote>} Finally, we were unable to 
validate all existing risk scores for people with type 2 diabetes due to the unavailability of 
some predictors, though risk scores which include variables that are generally not measured 
may be difficult to implement in clinical practice. We acknowledge that further research is 
needed to establish whether diabetes treatment contributes to CVD risk independently of 
other factors. Such research will be particularly valuable for new diabetes drugs that appear 
to have a beneficial effect on CVD in trial populations. 
Implications/Conclusions: 
Risk scores have important roles in guiding treatment, communicating risks to patients and 
for identifying eligible clinical trial participants. Unfortunately, we have shown that many 
existing risk scores do not accurately predict incident CVD risk in people with newly 
diagnosed type 2 diabetes, though risk scores developed in diabetes populations generally 
performed better than QRISK2. Current guidelines which recommend using QRISK2 would 
classify 87% of people with type 2 diabetes in Scotland as high risk leading to the potential 
over-treatment of low risk individuals. This approach is therefore not dissimilar to classifying 
all people aged over 40 years and with type 2 diabetes as high risk, as recommended in the 
current Scottish Intercollegiate Guidelines Network, American Diabetes Association and the 
European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in 
Clinical Practice recommendations.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} 
  
We conclude that there is scope to improve risk scores for incident CVD among people with 
type 2 diabetes and suggest that QRISK2 and the five diabetes-specific risk scores, without 
recalibration, do not currently meet the standard for application to real-world patients in 
Scotland.  
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Table 1. Characteristics of QRISK2 and five CVD risk scores in people with type 2 diabetes 
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10-year risk of CHD, 
stroke or transient 
ischaemic attack 
(ICD-10: I20, I22-I25, 
I63-I64). Not 
peripheral arterial 
disease.  
Age, sex, diabetes status, ethnicity, 
BMI, total:HDL cholesterol, systolic 
blood pressure, atrial fibrillation, 
smoking, treated-hypertension, 
Townsend social deprivation score, 
Rheumatoid arthritis, family history of 
CHD. 
Men: 0.792 
(0.789, 
0.794) 
Women: 
0.817 
(0.814, 
0.820) 
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I20-I21) PCI or 
CABG, fatal CHD 
(I20-I25), or non-fatal 
or fatal stroke (I61, 
I63, I64). 
Age, sex, diabetes duration, BMI, 
total:HDL cholesterol, SBP, HbA1c, 
smoking, treated hypertension, lipid-
lowering drugs, Micro & macro-
albuminuria, previous history of CVD  
0.72 
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Diabetes 
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people with 
a mean age 
of 64.1 
years from 
Fremantle, 
Western 
Australia 
Observational 
cohort study 
Recruitment: 
1993 to 
1996. 
Follow-up 
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Mean: 
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3</key></forei
gn-keys><ref-
type 
name="Journa
l 
Article">17</re
f-
type><contribu
tors><authors
><author>Elle
y, C. 
Raina</author
><author>Robi
nson, 
Elizabeth</aut
hor><author>
Kenealy, 
Tim</author><
author>Bramle
y, 
Dale</author>
<author>Drury
, Paul 
L.</author></a
uthors></contr
ibutors><titles
><title>Derivat
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Name Population Cohort Type Time-frame Follow-
up time, 
years 
Main Outcome Risk Factors Internal 
validation C 
statistic:  
ion and 
Validation of a 
New 
Cardiovascular 
Risk Score for 
People With 
Type 2 
Diabetes: The 
New Zealand 
Diabetes 
Cohort 
Study</title><s
econdary-
title>Diabetes 
Care</second
ary-
title></titles><
periodical><ful
l-title>Diabetes 
Care</full-
title></periodic
al><pages>13
47-
1352</pages>
<volume>33</
volume><num
ber>6</numbe
r><dates><ye
ar>2010</year
><pub-
dates><date>J
une 1, 
2010</date></
pub-
dates></dates
><urls><relate
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Name Population Cohort Type Time-frame Follow-
up time, 
years 
Main Outcome Risk Factors Internal 
validation C 
statistic:  
d-
urls><url>http:
//care.diabetes
journals.org/co
ntent/33/6/134
7.abstract</url
></related-
urls></urls><el
ectronic-
resource-
num>10.2337/
dc09-
1444</electron
ic-resource-
num></record
></Cite></End
Note>} 
Cardiovascular 
Health Study 
risk score{ 
ADDIN 
EN.CITE { 
ADDIN 
EN.CITE.DAT
A }} 
782 men 
people aged 
over 65 and 
without 
previous 
CVD from 
four field 
centres in 
the United 
States 
Observational 
cohort study 
Recruitment 
between 
1989 and 
1993. 
Follow-up 
until 1999 
Mean: 7 10-year risk of MI, 
stroke and death (No 
ICD codes provided) 
Age, sex, smoking status, HbA1c, 
systolic blood pressure, total 
cholesterol, HDL-cholesterol, 
creatinine, use of glucose-lowering 
medications 
0.64 
CHD: Coronary Heart Disease, BMI: Body mass index, HDL-cholesterol: High density lipoprotein cholesterol, PCI: Percutaneous coronary intervention, CABG: Coronary 
Artery Bypass Grafting, SBP: Systolic blood pressure, HbA1c: Glycated haemoglobin, MI: Myocardial infarction. 
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Table 2. Baseline characteristics of individuals diagnosed with type 2 diabetes in Scotland 
between 2004 and 2016 by subsequent five-year CVD outcome status over a median follow-
up of 4.9 years 
Characteristic  CVD event 
No CVD 
event 
N  14,081 167,318 
Median age at diagnosis, yrs (IQR)  66.5 (17.4) 59.3 (18) 
Sex (%) 
Men 8,292 (8.4) 90,604 (91.6) 
Women 5,789 (7) 76,714 (93) 
Ethnicity 
White 9,808 (7.6) 118,633 (92.4) 
SE-Asian 220 (5.4) 3,836 (94.6) 
Other 480 (6) 7,579 (94) 
SIMD (%) 
Most Deprived 3,700 (8.4) 40,349 (91.6) 
2 3,361 (8.2) 37,867 (91.8) 
3 2,780 (7.6) 33,569 (92.4) 
4 2,463 (7.5) 30,576 (92.5) 
Least Deprived 1,777 (6.6) 24,957 (93.4) 
Mean systolic blood pressure, mmHg (SD)  139.9 (19.9) 138.6 (17.7) 
Mean pulse pressure, mmHg (SD)  60.4 (16.3) 57 (14.7) 
Smoking status (%) 
Current smoker 3,854 (9.7) 35,946 (90.3) 
Ex-smoker 5,463 (8.9) 56,232 (91.1) 
Never smoker 4,699 (5.9) 74,493 (94.1) 
Mean BMI, kg/m (SD)  31.3 (6.5) 32.9 (6.9) 
Mean total:HDL cholesterol ratio (SD)  4.5 (1.6) 4.7 (1.6) 
Non-HDL cholesterol ratio, mmol/mol (SD)  3.9 (1.3) 4.1 (1.3) 
Mean glycated haemoglobin, mmol/L (SD)  64 (23) 64.8 (23.4) 
Mean glycated haemoglobin, % (SD)  8.0 (4.1) 8.1 (4.2) 
Albuminuria (%) 
Normal 5,664 (6.6) 80,735 (93.4) 
Micro 1,466 (9.3) 14,333 (90.7) 
Macro 215 (13.6) 1,361 (86.4) 
Albumin-creatinine ratio (SD)  5.3 (18.2) 3.3 (12.4) 
Prescribed anti-hypertensive medications 
(%) 
Yes 6,053 (9.3) 58,958 (90.7) 
No 8,028 (6.9) 108,360 (93.1) 
Prescribed rheumatoid arthritis 
medications (%) 
Yes 210 (9.7) 1,946 (90.3) 
No 13,871 (7.7) 165,372 (92.3) 
Atrial Fibrillation (%) 
Yes 1,487 (17.3) 7,098 (82.7) 
No 12,594 (7.3) 160,220 (92.7) 
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Retinopathy (%) 
Yes 1,735 (9.2) 17,068 (90.8) 
No 12,346 (7.6) 150,250 (92.4) 
Chronic Kidney Disease (%) 
Yes 3,547 (13.6) 22,454 (86.4) 
No 9,712 (6.7) 135,537 (93.3) 
Prescribed statins prior to diabetes 
diagnosis (%) 
Yes 4,509 (12.4) 31,962 (87.6) 
No 9,572 (6.6) 135,356 (93.4) 
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Table 3. Age-stratified calibration and discrimination statistics for QRISK2 and five 
diabetes-specific risk scores  
Risk 
score 
Age 
group 
Observed 
5-year 
risk 
Median 
predicted 
5-year 
risk, % 
(IQR) 
Calibration-
in-the-large 
Calibration 
slope 
C-statistic 
(Discrimination) 
QRISK2 Overall 9.7 24.07 
(21.21) 
-0.14 0.376 (0.376 
,0.377) 
0.674 (0.669, 
0.679) 
30-45 3.4 8.73 (9.71) -0.06 0.208 (0.208 
,0.208) 
0.666 (0.644, 
0.689) 
46-60 6.8 18.26 
(13.81) 
-0.11 0.272 (0.272 
,0.273) 
0.632 (0.623, 
0.641) 
61-75 11.5 29.51 
(16.54) 
-0.19 0.317 (0.317 
,0.317) 
0.604 (0.597, 
0.612) 
>75 21.0 45.01 
(17.55) 
-0.24 0.374 (0.374 
,0.375) 
0.578 (0.568, 
0.588) 
ADVANCE Overall 9.7 2.00 (2.53) 0.08 1.808 (1.805 
,1.811) 
0.666 (0.661, 
0.671) 
30-45 3.4 0.58 (0.45) 0.02 3.283 (3.277 
,3.289) 
0.628 (0.605, 
0.651) 
46-60 6.8 1.33 (0.96) 0.06 2.353 (2.350 
,2.356) 
0.595 (0.586, 
0.605) 
61-75 11.5 2.93 (2.09) 0.08 1.657 (1.655 
,1.660) 
0.594 (0.587, 
0.602) 
>75 21.0 6.27 (4.57) 0.15 0.973 (0.970 
,0.976) 
0.575 (0.565, 
0.585) 
CHS Overall 9.7 11.71 
(11.17) 
-0.02 0.631 (0.631 
,0.632) 
0.674 (0.669, 
0.679) 
30-45 3.4 4.58 (2.92) -0.02 0.760 (0.759 
,0.760) 
0.638 (0.615, 
0.661) 
46-60 6.8 8.68 (5.34) -0.02 0.742 (0.742 
,0.742) 
0.622 (0.613, 
0.632) 
61-75 11.5 16.1 (9.64) -0.05 0.546 (0.545 
,0.547) 
0.603 (0.596, 
0.611) 
>75 21.0 26.17 
(15.56) 
-0.05 0.398 (0.396 
,0.400) 
0.575 (0.565, 
0.585) 
Fremantle 
Diabetes 
Study 
Overall 9.7 5.24 (7.63) 0.05 0.738 (0.737 
,0.738) 
0.665 (0.660, 
0.670) 
30-45 3.4 1.2 (0.88) 0.02 2.025 (2.023 
,2.027) 
0.626 (0.603, 
0.648) 
46-60 6.8 3.23 (2.2) 0.04 1.157 (1.156 
,1.159) 
0.591 (0.582, 
0.600) 
61-75 11.5 8.49 (5.52) 0.03 0.736 (0.735 
,0.736) 
0.593 (0.585, 
0.600) 
>75 21.0 20.63 
(12.11) 
0.00 0.497 (0.496 
,0.497) 
0.580 (0.570, 
0.590) 
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NZ DCS Overall 9.7 16.17 
(10.87) 
-0.06 0.725 (0.725 
,0.725) 
0.670 (0.665, 
0.674) 
30-45 3.4 7.7 (2.9) -0.05 0.679 (0.676 
,0.683) 
0.645 (0.622, 
0.667) 
46-60 6.8 12.67 
(4.37) 
-0.06 0.740 (0.739 
,0.741) 
0.609 (0.599, 
0.618) 
61-75 11.5 20.23 
(6.39) 
-0.09 0.725 (0.725 
,0.726) 
0.599 (0.591, 
0.606) 
>75 21.0 30.45 
(8.42) 
-0.09 0.635 (0.633 
,0.638) 
0.573 (0.563, 
0.583) 
Swedish 
NDR 
Overall 9.7 8.26 (6.79) 0.02 0.955 (0.954 
,0.955) 
0.663 (0.658, 
0.668) 
30-45 3.4 3.67 (2.26) -0.01 0.871 (0.871 
,0.871) 
0.632 (0.609, 
0.654) 
46-60 6.8 6.44 (3.56) 0.01 0.869 (0.869 
,0.870) 
0.602 (0.592, 
0.611) 
61-75 11.5 10.54 
(5.62) 
0.00 0.727 (0.727 
,0.727) 
0.589 (0.582, 
0.596) 
>75 21.0 16.79 
(8.74) 
0.04 0.576 (0.575 
,0.576) 
0.566 (0.556, 
0.575) 
 
 
Figure Legends: 
Figure 1: Calibration plots for observed vs. predicted 5-year risk of CVD as estimated using 
QRISK2, ADVANCE, CHS, Fremantle Diabetes Study, New Zealand Diabetes Cohort Study 
and Swedish National Diabetes Register risk scores in people diagnosed with type 2 diabetes 
between 2004 and 2016 in Scotland† 
 
 
† Grey dashed line reflects perfect agreement between observed and predicted risk
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APPENDIX: Supplementary Materials 
Supplementary Table 1. Conversion of SIMD deciles from SCI-Diabetes to equivalent Townsend scores 
SIMD Decile Equivalent 2001 Townsend score 
Most deprived 6.83 
2 3.15 
3 1.44 
4 0.26 
5 -0.68 
6 -1.37 
7 -1.94 
8 -2.40 
9 -2.87 
Least deprived -3.51 
 
Supplementary Table 2. Probability of having a family history of coronary heart disease or stroke before 
60 years by age and SIMD. Taken from Scottish Health Survey 2014 (n=4610) { ADDIN EN.CITE 
<EndNote><Cite><Author>Brown</Author><Year>2014</Year><RecNum>557</RecNum><DisplayT
ext><style face="superscript">(22)</style></DisplayText><record><rec-number>557</rec-
number><foreign-keys><key app="EN" db-id="awe0xfst009dpuew5s0xdvwk2f2dvw20900s" 
timestamp="1517283004">557</key></foreign-keys><ref-type name="Report">27</ref-
type><contributors><authors><author>Brown, L., Christie, S., Gill, V., Gray, L., Hinchliffe, S., Ilic, N., 
Lepps, H., Leyland, A.H.,</author></authors><secondary-authors><author>The Scottish 
Government</author></secondary-authors></contributors><titles><title>The Scottish Health 
Survey</title><secondary-title>A National Statistics Publication for Scotland</secondary-
title></titles><dates><year>2014</year></dates><urls></urls></record></Cite></EndNote>} 
Age (years) 
SIMD Quintile 
1 (Most deprived) 2 3 4 5 (Least deprived) 
16-24.9 0.079 0.073 0.049 0.080 0.027 
25-34.9 0.230 0.165 0.134 0.115 0.019 
35-44.9 0.308 0.287 0.189 0.241 0.199 
45-54.9 0.435 0.396 0.297 0.285 0.244 
55-64.9 0.516 0.396 0.386 0.308 0.336 
65-74.9 0.388 0.383 0.358 0.323 0.345 
75 and above 0.297 0.318 0.285 0.298 0.238 
 
  
Supplementary Table 3. Extent of missing data within each incomplete variable 
Characteristic No. incomplete (%) 
Ethnicity 40,843 (27.3) 
Smoking status 712 (0.5) 
Systolic blood pressure 6,143 (4.1) 
Total cholesterol 10,039 (6.7) 
HDL-cholesterol 32,623 (21.8) 
Estimated Glomerular Filtration Rate 10,149 (6.8) 
Creatinine 9,742 (6.5) 
Glycated haemoglobin 10,019 (6.7) 
BMI at diagnosis 12,511 (8.4) 
Albuminuria 77,625 (51.9) 
Albumin:Creatinine ratio 85,289 (57) 
 
Supplementary Table 4. Number of individuals and events in people with 5-year predicted risks <10% 
or ≥10% as estimated using each risk score in population of people with type 2 diabetes in Scotland 
Risk score Predicted risk N (%) Events (%) 
QRISK ≥10 157397 (86.8) 13633 (96.82) 
 <10 24002 (13.2) 448 (3.18) 
ADVANCE ≥10 5838 (3.2) 1185 (8.42) 
 <10 175561 (96.8) 12896 (91.58) 
CHS ≥10 106662 (58.8) 11372 (80.76) 
 <10 74737 (41.2) 2709 (19.24) 
Fremantle ≥10 46820 (25.8) 6484 (46.05) 
 <10 134579 (74.2) 7597 (53.95) 
New Zealand DCS ≥10 149746 (82.6) 13330 (94.67) 
 <10 31653 (17.4) 751 (5.33) 
Swedish NDR ≥10 67672 (37.3) 8337 (59.21) 
 
<10 113727 (62.7) 5744 (40.79) 
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Supplementary Table 54. Calibration and discrimination statistics for QRISK2 and five diabetes-specific risk scores among subsets of the 
external validation cohort  
Subset N (%) Risk Score 
Observed 
5-year 
risk, % 
Median 
Predicted 
Risk, % (IQR) 
Calibration-
in-the-large Calibration Slope 
C-statistic 
(Discrimination) 
Individuals 
who had not 
previous 
been 
prescribed 
statins  
144,928 (79.9) QRISK2 8.4 
22.68 (21.02) -0.15 0.346 (0.346 ,0.346) 
0.683 (0.6778, 
0.6889) 
144,928 (79.9) ADVANCE 8.4 1.86 (2.43) 0.06 1.703 (1.700 ,1.706) 0.675 (0.6697, 0.680) 
144,928 (79.9) CHS 8.4 
10.92 (10.78) -0.03 0.590 (0.589 ,0.590) 
0.682 (0.6768, 
0.6988) 
144,928 (79.9) Fremantle DS 8.4 
4.71 (7.15) 0.03 0.688 (0.687 ,0.688) 
0.672 (0.6667, 
0.6768) 
144,928 (79.9) NZ DCS 8.4 15.37 (10.76) -0.07 0.668 (0.668 ,0.669) 0.6778 (0.671, 0.683) 
144,928 (79.9) Swedish NDR 8.4 7.95 (6.79) 0.00 0.887 (0.886 ,0.888) 0.672 (0.6667, 0.678) 
  
Individuals 
who had not 
been 
prescribed 
statins prior 
to diabetes 
diagnosis or 
during follow-
up 
73,343 (40.4) QRISK2 9.2 
22.67 (21.5) -0.14 0.380 (0.380 ,0.381) 
0.6859 (0.6778, 
0.694) 
73,343 (40.4) ADVANCE 9.2 
1.89 (2.61) 0.07 1.860 (1.857 ,1.863) 
0.6788 (0.670, 
0.6869) 
73,343 (40.4) CHS 9.2 11.29 (11.72) -0.02 0.620 (0.620 ,0.621) 0.682 (0.673, 0.690) 
73,343 (40.4) Fremantle DS 9.2 5.09 (8.12) 0.04 0.678 (0.677 ,0.679) 0.673 (0.664, 0.681) 
73,343 (40.4) NZ DCS 9.2 15.74 (11.53) -0.07 0.696 (0.695 ,0.696) 0.6798 (0.671, 0.698) 
73,343 (40.4) Swedish NDR 9.2 7.98 (7.13) 0.01 0.937 (0.937 ,0.937) 0.672 (0.663, 0.680) 
  
Individuals 
for which 
proxy 
variables 
replaced with 
null or mean 
values 
181,399 (100.0) QRISK2 9.7 21.49 (19.23) -0.11 0.398 (0.398 ,0.398) 0.669 (0.665, 0.674) 
181,399 (100.0) ADVANCE 9.7 2.00 (2.53) 0.08 1.808 (1.805 ,1.811) 0.666 (0.661, 0.671) 
181,399 (100.0) CHS 9.7 11.71 (11.17) -0.02 0.631 (0.631 ,0.632) 0.674 (0.669, 0.679) 
181,399 (100.0) Fremantle DS 9.7 5.24 (7.63) 0.05 0.738 (0.737 ,0.738) 0.665 (0.660, 0.607) 
181,399 (100.0) NZ DCS 9.7 16.17 (10.87) -0.06 0.725 (0.725 ,0.725) 0.670 (0.665, 0.674) 
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181,399 (100.0) Swedish NDR 9.7 8.26 (6.79) 0.02 0.955 (0.954 ,0.955) 0.663 (0.658, 0.668) 
        
Individuals 
with 
complete 
data 
109,195 (60.2) QRISK2 9.1 23.69 (20.7) -0.1547 0.319 (0.319 ,0.319) 0.661 (0.656, 0.667) 
85,794 (47.3) ADVANCE 9.3 2.06 (2.6) 0.0769 1.642 (1.639 ,1.645) 0.664 (0.657, 0.671) 
145,764 (80.4) CHS 9.7 11.77 (11.08) -0.0218 0.607 (0.606 ,0.607) 0.667 (0.662, 0.672) 
65,972 (36.4) Fremantle DS 9.0 5.24 (7.52) 0.0438 0.628 (0.627 ,0.629) 0.660 (0.652, 0.668) 
71,389 (39.4) NZ DCS 8.9 16.13 (10.65) -0.071 0.635 (0.634 ,0.635) 0.662 (0.655, 0.670) 
90,762 (50.0) Swedish NDR 9.2 8.38 (6.80) 0.0106 0.889 (0.889 ,0.890) 0.661 (0.654, 0.667) 
        
Individuals 
diagnosed 
with type 2 
diabetes < 
2011 
103,383 (57.0) QRISK2 10.0 24.7 (21.99) -0.15 0.38 (0.38 ,0.38) 0.674 (0.668, 0.680) 
103,383 (57.0) ADVANCE 10.0 2.04 (2.58) 0.08 1.91 (1.9 ,1.91) 0.667 (0.661, 0.673) 
103,383 (57.0) CHS 10.0 11.94 (11.47) -0.02 0.64 (0.64 ,0.64) 0.675 (0.669, 0.680) 
103,383 (57.0) Fremantle DS 10.0 5.33 (7.74) 0.05 0.77 (0.77 ,0.77) 0.667 (0.661, 0.673) 
103,383 (57.0) NZ DCS 10.0 16.42 (11.03) -0.06 0.75 (0.75 ,0.75) 0.671 (0.665, 0.676) 
103,383 (57.0) Swedish NDR 10.0 8.32 (6.86) 0.02 0.97 (0.97 ,0.98) 0.664 (0.658, 0.669) 
        
Individuals 
diagnosed 
with type 2 
diabetes ≥ 
2011 
78,016 (43.0) QRISK2 9.2 23.29 (20.18) -0.14 0.36 (0.36 ,0.36) 0.673 (0.663, 0.682) 
78,016 (43.0) ADVANCE 9.2 1.94 (2.47) 0.07 1.65 (1.65 ,1.66) 0.665 (0.655, 0.674) 
78,016 (43.0) CHS 9.2 11.42 (10.82) -0.02 0.59 (0.59 ,0.59) 0.672 (0.662, 0.681) 
78,016 (43.0) Fremantle DS 9.2 5.11 (7.46) 0.04 0.66 (0.66 ,0.66) 0.662 (0.653, 0.671) 
78,016 (43.0) NZ DCS 9.2 15.84 (10.65) -0.07 0.66 (0.66 ,0.66) 0.668 (0.658, 0.677) 
78,016 (43.0) Swedish NDR 9.2 8.17 (6.67) 0.01 0.88 (0.88 ,0.88) 0.661 (0.651, 0.670) 
 
 
 
 
Supplementary Table 6. Calibration and discrimination statistics for QRISK2 and five diabetes-specific risk scores among people with type 2 
diabetes (includes prevalent cases, n=240,266)  
Risk Score 
Observed 5-
year risk, % 
Median Predicted 
Risk, % (IQR) 
Calibration-in-the-
large Calibration Slope C-statistic (Discrimination) 
QRISK2 11.5 21.58 (19.92) -0.10 0.42 (0.42 ,0.42) 0.662 (0.658, 0.666) 
ADVANCE 11.5 2.48 (3.47) 0.09 1.77 (1.77 ,1.78) 0.690 (0.686, 0.694) 
CHS 11.5 10.42 (10.21) 0.01 0.64 (0.64 ,0.64) 0.640 (0.636, 0.644) 
Fremantle DS 11.5 4.42 (6.52) 0.07 0.79 (0.79 ,0.80) 0.646 (0.642, 0.650) 
NZ DCS 11.5 18.33 (12.95) -0.07 0.77 (0.77 ,0.77) 0.687 (0.684, 0.691) 
Swedish NDR 11.5 8.81 (7.51) 0.03 1.18 (1.18 ,1.18) 0.688 (0.684, 0.692) 
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Supplementary Figure 1 Distribution of predicted 5-year risk of CVD for QRISK2, ADVANCE, 
Cardiovascular Health Study, Fremantle Diabetes Study, New Zealand DCS and Swedish NDR. Dashed 
grey line reflects median predicted risk 
  
 
Supplementary Figure 2. Calibration plots for observed vs. predicted 5-year risk of CVD for QRISK2, 
ADVANCE, CHS, Fremantle Diabetes Study, New Zealand Diabetes Cohort Study and Swedish NDR 
following recalibration 
 
Supplementary Figure 3. Calibration plots for observed vs. predicted 5-year risk of CVD for QRISK2, 
ADVANCE, CHS, Fremantle Diabetes Study, NZ DCS and Swedish NDR among individuals who had 
not been prescribed statins prior to diabetes diagnosis in Scotland (n=144,928) 
 
 
Supplementary Figure 4. Calibration plots for observed vs. predicted 5-year risk of CVD for QRISK2, 
ADVANCE, CHS, Fremantle Diabetes Study, NZ DCS and Swedish NDR among individuals who had 
not been prescribed statins prior to diabetes diagnosis or during follow-up in Scotland (n=73,343) 
 
  
 
Supplementary Figure 5. Calibration plots for observed vs. predicted 5-year risk of CVD for QRISK2, 
ADVANCE, Cardiovascular Health Study, Fremantle DS, New Zealand DCS and Swedish NDR in 
people diagnosed with type 2 diabetes between 2004 and 2016 in Scotland. (Proxy variables 
replaced with null values)
 Supplementary Figure 6. Calibration plots for observed vs. predicted 5-year risk of CVD for 
QRISK2, ADVANCE, Cardiovascular Health Study, Fremantle DS, New Zealand DCS and Swedish 
NDR in people diagnosed with type 2 diabetes in Scotland. Predicted risk estimated at latest of 
01/01/2010, date of diabetes diagnosis or date of 30th birthday.  
Formatted: Font: Italic, Underline
Formatted: Font: Bold
Formatted: No widow/orphan control, Don't keep with
next
Formatted: Superscript
  
 
 
 
Supplementary Figure 67. Calibration plots for observed vs. predicted 5-year risk of CVD for QRISK2, 
ADVANCE, Cardiovascular Health Study, Fremantle DS, New Zealand DCS and Swedish 
NDR following complete case analysis in people diagnosed with type 2 diabetes between 2004 and 
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2016 in Scotland. 
 
 
 
 
 
